Gilead Science and LEO Pharma合作伙伴开发新的流行性疾病的口服治疗。 Gilead Sciences and LEO Pharma partner to develop new oral treatment for inflammatory diseases.

Gilead Sciences和LEO Pharma建立了战略伙伴关系,以制定口服STAT6方案,治疗多种发炎性疾病。 Gilead Sciences and LEO Pharma have formed a strategic partnership to develop an oral STAT6 program, which could treat multiple inflammatory diseases. 合作的目的是加速该方案的发展和潜在的市场进入,针对的条件是外皮性皮炎和哮喘等。 The collaboration aims to accelerate the development and potential market entry of the program, targeting conditions like atopic dermatitis and asthma. 交易条款未披露。 Terms of the deal were not disclosed.